Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q2V2M9
UPID:
FHOD3_HUMAN
Alternative names:
Formactin-2; Formin homolog overexpressed in spleen 2
Alternative UPACC:
Q2V2M9; A8MQT4; E5F5Q0; Q642I2; Q6ZRQ7; Q86TF9; Q8N3A5; Q9C0G8; Q9H604; Q9H6G7
Background:
FH1/FH2 domain-containing protein 3, also known as Formactin-2 or Formin homolog overexpressed in spleen 2, plays a crucial role in actin-organizing, promoting stress fiber formation and cell elongation. This protein's involvement in actin filament polymerization, especially in cardiomyocytes, underscores its significance in cellular structure and motility.
Therapeutic significance:
Linked to Cardiomyopathy, familial hypertrophic, 28 (CMH28), a heart disorder with symptoms like dyspnea and chest pain, FH1/FH2 domain-containing protein 3's genetic variants highlight its potential as a target for therapeutic intervention. Understanding its role could pave the way for novel treatments for cardiac diseases.